Neal Shore, MD, FACS, highlights the efficacy data from the EMBARK study, toxicities observed with enzalutamide alone or in combination with a LHRH agonist, and the significance of the FDA approval of enzalutamide for patients with nonmetastatic castration-sensitive prostate cancer.
The FDA has approved enzalutamide for the treatment of patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
The FDA has accepted and granted priority review to a supplemental new drug application seeking the approval of enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.